Brazilian Healthcare: Sindusfarma Monthly Prescription (June 23): Growth Slowdown
Sindusfarma data continued to show a slowdown on retail pharma sales with sell-in and and sell-out (considering PMB as proxy) growth reaching +10.2% and +6.5% y/y in June, respectively, (+13.5% and +9.9% y/y during 2Q23, respectively), reflecting not only a lower pricing baseline from April onwards (CMED from 10.9% in 2022 to 5.6% in 2023), but also tough volume comps (i.e., sell-in volumes -3% y/y in June). Elsewhere, Generics sell-in sales also decelerated and reached +15.6%y/y in Jun (or +20.4%y/y in 2Q23), also dragged by weaker volumes (+1.2%y/y). Overall, sales trends seem very in line with our current +10% y/y sell-out forecast for HYPE3 during 2Q23, which might start to evolve during 2H23 with easier volume comps.

